ICER’s DMD recommendations include changes to outcome measures, pricing

After finding that all three DMD therapies it reviewed lack clinical data to support a high price, ICER recommended that manufacturers and payers implement pricing policies better aligned with their value and suggested trial endpoints that could help companies better determine therapeutic benefits.

In its final evidence report, the Institute for Clinical and Economic Review said drugs with accelerated approval, like Exondys 51 eteplirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT), and those that have not demonstrated clinical benefit should be priced closer to marginal cost of production until clinical benefits are proven...